Shared on 08 Aug 25
Fair value Increased 14%AI And Immunotherapy Advances Will Define Oncology's Future
Upward revisions to Compugen's revenue growth and net profit margin forecasts have driven a notable increase in its consensus analyst price target, which has risen from $5.50 to $6.25. What's in the News Compugen dosed the first patient in a global randomized sub-trial (MAIA-ovarian), evaluating its potential first-in-class anti-PVRIG antibody COM701 as maintenance therapy for relapsed platinum sensitive ovarian cancer.
Shared on 01 May 25
Fair value Increased 38%Partnerships With AstraZeneca And Gilead Will Open New Market Opportunities
Shared on 23 Apr 25
Partnerships With AstraZeneca And Gilead Will Open New Market Opportunities
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
Partnerships With AstraZeneca And Gilead Will Open New Market Opportunities
AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3% and increased future PE multiple from 58.7x to 65.5x.
Shared on 09 Apr 25
Partnerships With AstraZeneca And Gilead Will Open New Market Opportunities
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Increased 0.25%Partnerships With AstraZeneca And Gilead Will Open New Market Opportunities
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
Partnerships With AstraZeneca And Gilead Will Open New Market Opportunities
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
Fair value Decreased 28%Partnerships With AstraZeneca And Gilead Will Open New Market Opportunities
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 12 Mar 25